From the Guidelines
An irregular regular heartbeat, also known as an arrhythmia, requires immediate medical evaluation to determine the underlying cause and appropriate treatment, as it can be a symptom of a life-threatening condition. If you're experiencing this symptom, contact your healthcare provider or seek emergency care if accompanied by chest pain, shortness of breath, or dizziness. According to the 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia 1, common arrhythmias include atrial fibrillation, premature beats, and tachycardia.
Key Considerations
- Treatment depends on the specific type and severity of the arrhythmia, but may include medications like beta-blockers (metoprolol 25-100mg daily), calcium channel blockers (diltiazem 120-360mg daily), or antiarrhythmics (amiodarone 200mg daily) 2, 3, 4.
- Some patients require procedures such as cardioversion, ablation, or pacemaker implantation 5, 6.
- While waiting for medical care, avoid stimulants like caffeine and alcohol, practice stress reduction techniques, and monitor your pulse.
- Arrhythmias occur when the electrical signals controlling your heartbeat malfunction, which can happen due to heart disease, electrolyte imbalances, medication side effects, or structural heart abnormalities 7, 8.
- Self-diagnosis is dangerous as many arrhythmias have similar symptoms but require different treatments 9.
Importance of Medical Evaluation
A thorough medical evaluation is crucial to determine the underlying cause of the arrhythmia and to develop an effective treatment plan. This evaluation should include a clinical history, physical examination, and diagnostic tests such as electrocardiogram (ECG) and echocardiogram 1, 9.
Conclusion is not allowed, so the response will be ended here.
From the FDA Drug Label
High doses of digoxin may produce a variety of rhythm disturbances, such as first-degree, second-degree (Wenckebach), or third-degree heart block (including asystole); atrial tachycardia with block; AV dissociation; accelerated junctional (nodal) rhythm; unifocal or multiform ventricular premature contractions (especially bigeminy or trigeminy); ventricular tachycardia; and ventricular fibrillation.
The drug digoxin can cause irregular heartbeat due to various rhythm disturbances at high doses, including atrial tachycardia, ventricular tachycardia, and ventricular fibrillation 10.
- Key points:
- High doses of digoxin can lead to rhythm disturbances.
- These disturbances can include irregular heartbeats such as atrial and ventricular tachycardia.
- The risk of these disturbances can be mitigated by adjusting the dose of digoxin.
From the Research
Irregular Regular Heartbeat
- An irregular regular heartbeat, also known as atrial fibrillation (AF), is a common heart condition characterized by an irregular and often rapid heart rate 11.
- The management of AF typically involves either rhythm control or rate control, with the goal of preventing complications such as stroke and heart failure 11.
- Rate control is often achieved using beta-blockers, which are usually required to achieve adequate ventricular rate control, defined as a resting rate of less than 100 beats per minute 11.
- Non-dihydropyridine calcium channel blockers are often contraindicated in patients with AF and heart failure with systolic dysfunction, and digoxin may be used in combination with a beta-blocker to achieve satisfactory rate control 11.
Treatment Options
- Beta-blockers are commonly used to treat AF, but their efficacy and safety have been debated, particularly in patients with heart failure and reduced ejection fraction 11.
- Apixaban, a non-vitamin K antagonist oral anticoagulant (NOAC), has been shown to be effective and safe in patients with AF, including those with bioprosthetic valve replacement or valve repair 12.
- A comparison of NOACs, including apixaban, dabigatran, and rivaroxaban, found that they were more effective than warfarin in preventing stroke, but had varying risks of bleeding 13.
- In patients with AF and aortic stenosis, NOACs were associated with a higher risk of thromboembolism but a lower risk of major bleeding compared to warfarin 14.
Key Findings
- The choice of treatment for AF depends on various factors, including the presence of heart failure, systolic dysfunction, and other comorbidities 11.
- NOACs, such as apixaban, may be a reasonable option for patients with AF, including those with bioprosthetic valve replacement or valve repair, and those with aortic stenosis 12, 14.
- However, the efficacy and safety of NOACs compared to warfarin may vary depending on the specific patient population and clinical context 13, 14.